Scholar Rock Holding (SRRK) Assets Average (2018 - 2026)
Scholar Rock Holding's quarterly Assets Average came in at $469.8 million in Q1 2026, up 6.46% year-on-year from $441.2 million in Q1 2025, and up 15.14% quarter-over-quarter from $408.0 million in Q4 2025.
Scholar Rock Holding has reported Assets Average for 9 years, with the latest figure at $469.8 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 6.46% year-over-year to $469.8 million; the trailing twelve-month figure through Mar 2026 stood at $469.8 million (up 6.46% YoY), and the FY2025 full-year result was $439.6 million, up 11.86% from the prior year.
- Assets Average for Q1 2026 stood at $469.8 million, up from $408.0 million in the prior quarter.
- The five-year high for Assets Average was $469.8 million in Q1 2026, with the low at $203.0 million in Q3 2024.
- Average Assets Average over 5 years is $337.2 million, with a median of $336.4 million recorded in 2023.
- Year-over-year, Assets Average sank 34.24% in 2023 and surged 85.16% in 2025.
- Tracing SRRK's Assets Average over 5 years: stood at $374.2 million in 2022, then declined by 24.95% to $280.9 million in 2023, then rose by 16.44% to $327.0 million in 2024, then grew by 24.76% to $408.0 million in 2025, then gained by 15.14% to $469.8 million in 2026.
- The last three Assets Average figures came in at $469.8 million (Q1 2026), $408.0 million (Q4 2025), and $375.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 469.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 469.76 Mn |
| Dec 31, 2025 | 408.00 Mn |
| Sep 30, 2025 | 375.88 Mn |
| Jun 30, 2025 | 373.80 Mn |
| Mar 31, 2025 | 441.24 Mn |
| Dec 31, 2024 | 327.03 Mn |
| Sep 30, 2024 | 203.00 Mn |
| Jun 30, 2024 | 247.08 Mn |
| Mar 31, 2024 | 289.16 Mn |
| Dec 31, 2023 | 280.86 Mn |
| Sep 30, 2023 | 267.79 Mn |
| Jun 30, 2023 | 299.81 Mn |
| Mar 31, 2023 | 336.44 Mn |
| Dec 31, 2022 | 374.24 Mn |
| Sep 30, 2022 | 407.22 Mn |
| Jun 30, 2022 | 345.05 Mn |
| Mar 31, 2022 | 285.21 Mn |
| Dec 31, 2021 | 301.42 Mn |
| Sep 30, 2021 | 315.22 Mn |
| Jun 30, 2021 | 346.32 Mn |
| Mar 31, 2021 | 374.45 Mn |
| Dec 31, 2020 | 275.86 Mn |
| Sep 30, 2020 | 159.89 Mn |
| Jun 30, 2020 | 166.03 Mn |
| Mar 31, 2020 | 186.04 Mn |
| Dec 31, 2019 | 192.46 Mn |
| Sep 30, 2019 | 192.73 Mn |
| Jun 30, 2019 | 183.95 Mn |
| Mar 31, 2019 | 176.16 Mn |
| Dec 31, 2018 | 145.18 Mn |
| Sep 30, 2018 | 114.00 Mn |